Showing results (41-50 of 170) with videos related to

Sort By:
Pageof 17
Cancer Research|June 17, 2006
Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132Lisa J A Crawford, Brian Walker, Huib Ovaa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma CellsDeepika Sharma Das, Abhishek Das, Arghya Ray, et al.
Blood|November 17, 2007
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myelomaDharminder Chauhan, Ajita Singh, Mohan Brahmandam, et al.
British Journal of Haematology|December 1, 2010
PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivoAjita V Singh, Madhavi Bandi, Monette A Aujay, et al.
Expert Review of Proteomics|November 15, 2018
The power of proteasome inhibition in multiple myelomaThomas A Guerrero-Garcia, Sara Gandolfi, Jacob P Laubach, et al.
Hematology/Oncology Clinics of North America|November 13, 2007
The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapiesConstantine S Mitsiades, Douglas W McMillin, Steffen Klippel, et al.
Molecular Cancer Therapeutics|December 21, 2002
Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironmentToshiaki Hayashi, Teru Hideshima, Masaharu Akiyama, et al.
British Journal of Haematology|April 22, 2016
A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cellsArghya Ray, Durgadevi Ravillah, Deepika S Das, et al.
Blood|September 1, 2010
A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myelomaDharminder Chauhan, Ajita V Singh, Monette Aujay, et al.
British Journal of Haematology|February 21, 2006
FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myelomaShaji Kumar, Noopur Raje, Teru Hideshima, et al.
Pageof 17